JP2024071397A5 - - Google Patents

Download PDF

Info

Publication number
JP2024071397A5
JP2024071397A5 JP2024031305A JP2024031305A JP2024071397A5 JP 2024071397 A5 JP2024071397 A5 JP 2024071397A5 JP 2024031305 A JP2024031305 A JP 2024031305A JP 2024031305 A JP2024031305 A JP 2024031305A JP 2024071397 A5 JP2024071397 A5 JP 2024071397A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
dry powder
composition
fibrosis
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024031305A
Other languages
English (en)
Japanese (ja)
Other versions
JP7737492B2 (ja
JP2024071397A (ja
Filing date
Publication date
Priority claimed from PCT/US2019/050332 external-priority patent/WO2020055812A1/en
Application filed filed Critical
Publication of JP2024071397A publication Critical patent/JP2024071397A/ja
Publication of JP2024071397A5 publication Critical patent/JP2024071397A5/ja
Priority to JP2025142971A priority Critical patent/JP2025184877A/ja
Application granted granted Critical
Publication of JP7737492B2 publication Critical patent/JP7737492B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024031305A 2018-09-10 2024-03-01 Cav-1タンパク質の修飾ペプチドフラグメント及び線維症の治療におけるその使用 Active JP7737492B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025142971A JP2025184877A (ja) 2018-09-10 2025-08-29 Cav-1タンパク質の修飾ペプチドフラグメント及び線維症の治療におけるその使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862728997P 2018-09-10 2018-09-10
US62/728,997 2018-09-10
PCT/US2019/050332 WO2020055812A1 (en) 2018-09-10 2019-09-10 Modified peptide fragments of cav-1 protein and the use thereof in the treatment of fibrosis
JP2021538170A JP7496826B2 (ja) 2018-09-10 2019-09-10 Cav-1タンパク質の修飾ペプチドフラグメント及び線維症の治療におけるその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021538170A Division JP7496826B2 (ja) 2018-09-10 2019-09-10 Cav-1タンパク質の修飾ペプチドフラグメント及び線維症の治療におけるその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025142971A Division JP2025184877A (ja) 2018-09-10 2025-08-29 Cav-1タンパク質の修飾ペプチドフラグメント及び線維症の治療におけるその使用

Publications (3)

Publication Number Publication Date
JP2024071397A JP2024071397A (ja) 2024-05-24
JP2024071397A5 true JP2024071397A5 (enExample) 2024-08-26
JP7737492B2 JP7737492B2 (ja) 2025-09-10

Family

ID=69778115

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021538170A Active JP7496826B2 (ja) 2018-09-10 2019-09-10 Cav-1タンパク質の修飾ペプチドフラグメント及び線維症の治療におけるその使用
JP2024031305A Active JP7737492B2 (ja) 2018-09-10 2024-03-01 Cav-1タンパク質の修飾ペプチドフラグメント及び線維症の治療におけるその使用
JP2025142971A Pending JP2025184877A (ja) 2018-09-10 2025-08-29 Cav-1タンパク質の修飾ペプチドフラグメント及び線維症の治療におけるその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021538170A Active JP7496826B2 (ja) 2018-09-10 2019-09-10 Cav-1タンパク質の修飾ペプチドフラグメント及び線維症の治療におけるその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025142971A Pending JP2025184877A (ja) 2018-09-10 2025-08-29 Cav-1タンパク質の修飾ペプチドフラグメント及び線維症の治療におけるその使用

Country Status (9)

Country Link
US (4) US11905336B2 (enExample)
EP (1) EP3849580A4 (enExample)
JP (3) JP7496826B2 (enExample)
KR (2) KR102958241B1 (enExample)
CN (2) CN121159628A (enExample)
AU (2) AU2019339260B2 (enExample)
BR (1) BR112021004404A2 (enExample)
CA (2) CA3111563A1 (enExample)
WO (1) WO2020055812A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230148263A (ko) 2013-03-15 2023-10-24 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 누트린-3a 및 펩티드에 의한 폐 섬유증의 저해
KR102958241B1 (ko) 2018-09-10 2026-04-30 레인 테라퓨틱스, 인크. Cav-1 단백질의 변형된 펩타이드 단편 및 섬유증의 치료에 있어서 이의 용도
WO2020185826A1 (en) * 2019-03-11 2020-09-17 Lung Therapeutics, Inc. Compositions and methods for protecting type 2 alveolar epithelial cells (aec2)
WO2021216659A1 (en) * 2020-04-21 2021-10-28 Lung Therapeutics, Inc. Modified peptide fragments of cav-1 protein and uses thereof
EP4168031A4 (en) * 2020-06-19 2024-07-10 Lung Therapeutics, LLC MODIFIED CAVEOLIN-1 PEPTIDES FOR THE TREATMENT OF PATHOGEN-INDUCED LUNG LESION
EP4297768A4 (en) 2021-02-25 2025-01-15 Lung Therapeutics, LLC Biomarkers for the treatment of interstitial lung disease
US20250041383A1 (en) * 2021-06-17 2025-02-06 Lung Therapeutics, Inc. Modified caveolin-1 peptides for the treatment of post-acute covid-19
JP2024539242A (ja) * 2021-10-22 2024-10-28 ラング セラピューティクス,エルエルシー 慢性腎疾患の治療のための改変カベオリン-1ペプチド
EP4554605A4 (en) * 2022-07-12 2026-06-17 Rein Therapeutics Inc MODIFIED CAVELOIN-1 PEPTIDE FORMULATIONS AND THEIR METHODS OF MANUFACTURING AND USING
CN119661656B (zh) * 2024-11-20 2026-05-15 华中科技大学同济医学院附属梨园医院 一种靶向拮抗pCAV1的多肽及其应用

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4021387A (en) 1975-11-19 1977-05-03 President And Fellows Of Harvard College Eosinophilotactic tetrapeptides
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
IT1190891B (it) 1982-06-24 1988-02-24 Anic Spa Metodo per la sintesi in fase solida di polipeptidi retroinvertiti
US4816449A (en) 1984-08-09 1989-03-28 Immunetech Pharmaceuticals Immunotherapeutic anti-inflammatory peptide agents
US4613676A (en) 1983-11-23 1986-09-23 Ciba-Geigy Corporation Substituted 5-amino-4-hydroxyvaleryl derivatives
ZA846192B (en) 1984-08-09 1986-03-26 Merck Patent Gmbh Immunotherapeutic polypeptide agents
US5728680A (en) 1987-12-30 1998-03-17 Cytoven J.V. Methods for normalizing numbers of lymphocytes
DK53291D0 (da) 1991-03-25 1991-03-25 Carlbiotech Ltd As Smaa peptider og peptidrelaterede stoffer samt farmaceutiske praeparater indeholdende saadanne forbindelser
US6629646B1 (en) 1991-04-24 2003-10-07 Aerogen, Inc. Droplet ejector with oscillating tapered aperture
US6540154B1 (en) 1991-04-24 2003-04-01 Aerogen, Inc. Systems and methods for controlling fluid feed to an aerosol generator
US5938117A (en) 1991-04-24 1999-08-17 Aerogen, Inc. Methods and apparatus for dispensing liquids as an atomized spray
US5277175A (en) 1991-07-12 1994-01-11 Riggs John H Continuous flow nebulizer apparatus and method, having means maintaining a constant-level reservoir
GB9120005D0 (en) 1991-09-19 1991-11-06 Wellcome Found Method of administering phospholipid dispersions
US5355872B1 (en) 1992-03-04 1998-10-20 John H Riggs Low flow rate nebulizer apparatus and method of nebulization
US5284133A (en) 1992-07-23 1994-02-08 Armstrong Pharmaceuticals, Inc. Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means
US5329028A (en) 1992-08-05 1994-07-12 Genentech, Inc. Carbohydrate-directed cross-linking reagents
KR950702839A (ko) 1992-08-27 1995-08-23 스티븐 딕 레트로, 인버소-, 및 레트로- 인버소 합성 펩티드 유사체(retro-, inverso-, and retro-inverso synthetic peptide analogues)
EP0945504A3 (en) 1992-12-11 1999-12-08 The University Of Florida Materials and method for control of pests
US5559209A (en) 1993-02-18 1996-09-24 The General Hospital Corporation Regulator regions of G proteins
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US5797389A (en) 1995-09-06 1998-08-25 Ryder; Steven L. Variable oxygen concentration high-flow nebulizer
US5823179A (en) 1996-02-13 1998-10-20 1263152 Ontario Inc. Nebulizer apparatus and method
ES2140998B1 (es) 1996-05-13 2000-10-16 Univ Sevilla Procedimiento de atomizacion de liquidos.
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
US6017735A (en) 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
US20030113271A1 (en) 1997-01-29 2003-06-19 University Technology Corporation Formulations for pulmonary delivery
IT1291122B1 (it) 1997-03-28 1998-12-29 Sar Spa Micropompa per la nebulizzazione di fluidi con valvola dosatrice perfezionata
US6096707A (en) 1997-07-11 2000-08-01 Biotie Therapies Ltd. Integrin binding peptide and use thereof
US6044841A (en) 1997-08-29 2000-04-04 1263152 Ontario Inc. Breath actuated nebulizer with valve assembly having a relief piston
US6041776A (en) 1998-05-14 2000-03-28 Briggs, Iii; Stephen W. Medical nebulization device
US6354516B1 (en) 1999-11-02 2002-03-12 Aradigm Corporation Pore structures for reduced pressure aerosolization
SE9900369D0 (sv) 1999-02-04 1999-02-04 Siemens Elema Ab Ultrasonic nebuliser
US6328030B1 (en) 1999-03-12 2001-12-11 Daniel E. Kidwell Nebulizer for ventilation system
EP1076091A1 (en) 1999-08-09 2001-02-14 Universite Catholique De Louvain Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds
AU2001280917A1 (en) 2000-08-02 2002-02-13 Research Development Foundation Jet nebulizer assembly for home administration of drugs in aerosols
US20020077283A1 (en) 2000-09-08 2002-06-20 Sessa William C. Caveolin peptides and their use as therapeutics
US6732944B2 (en) 2001-05-02 2004-05-11 Aerogen, Inc. Base isolated nebulizing device and methods
GB0119852D0 (en) 2001-08-15 2001-10-10 Univ York Baculovirus
WO2003057291A1 (en) 2002-01-07 2003-07-17 Aerogen, Inc. Devices and methods for nebulizing fluids for inhalation
JP4761709B2 (ja) 2002-01-15 2011-08-31 エアロジェン,インコーポレイテッド エアロゾル発生器を作動するための方法およびシステム
US7332469B2 (en) 2002-04-05 2008-02-19 Board Of Regents The University Of Texas System Intrapleural single-chain urokinase alone or complexed to its soluble receptor protects against pleural adhesions
EP1501479A1 (en) 2002-05-07 2005-02-02 Nektar Therapeutics Capsules for dry powder inhalers and methods of making and using same
US20040175384A1 (en) 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US20070207158A1 (en) 2003-06-17 2007-09-06 Harrison Roger G Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
WO2005092301A1 (en) 2004-03-26 2005-10-06 Universita' Degli Studi Di Parma Insulin highly respirable microparticles
PL1765397T3 (pl) 2004-05-25 2013-04-30 Tactic Pharma Llc Hamujące przeciwciała wiążące kompleks aktywatora plazminogenu typu urokinazy (uPA) i jego receptora (uPAR)
NZ563360A (en) 2005-05-25 2011-04-29 Aerogen Inc Aerosolising liquid using an apertured membrane aligned within a peizoelectric ring
TWI299993B (en) 2005-12-15 2008-08-21 Dev Center Biotechnology Aqueous inhalation pharmaceutical composition
US8058227B2 (en) 2006-10-03 2011-11-15 Medical University Of South Carolina Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD
JP2010506860A (ja) * 2006-10-19 2010-03-04 アンジオケム,インコーポレーテッド P−糖タンパク質機能を刺激するための化合物およびその使用
US20090068258A1 (en) 2007-08-28 2009-03-12 Lisanti Michael P Caveolin-mimetic peptide for prevention and treatment of pulmonary hypertension and right ventricular hypertrophy
EP2220115A2 (en) 2007-12-13 2010-08-25 Glaxo Group Limited Polypeptides, antibody variable domains & antagonists
WO2009111625A2 (en) * 2008-03-05 2009-09-11 Board Of Regents, The University Of Texas System Peptide inhibition of lung epithelial apoptosis and pulmonary fibrosis
WO2009152453A2 (en) 2008-06-12 2009-12-17 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating pulmonary hypertension
AU2009291747B2 (en) 2008-09-10 2016-05-26 Genentech, Inc. Methods for inhibiting ocular angiogenesis
EP2349314B1 (en) 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
GB2466121B (en) 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
WO2010132864A1 (en) 2009-05-15 2010-11-18 Intermune, Inc. Methods of treating hiv patients with anti-fibrotics
MX2012003171A (es) 2009-09-28 2012-04-11 Hoffmann La Roche Novedosos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
SI2533761T1 (sl) 2010-02-11 2019-08-30 Ablynx N.V. Postopki in sestavki za pripravo aerosolov
WO2012061828A2 (en) * 2010-11-05 2012-05-10 The Regents Of The University Of California Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord
WO2013148232A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
WO2013184482A1 (en) 2012-06-04 2013-12-12 Yale University Method of treating and preventing ocular angiogenesis
KR20180092324A (ko) 2013-03-13 2018-08-20 포레스트 래보러토리즈 홀딩스 리미티드 미분화된 약제학적 조성물
KR20230148263A (ko) 2013-03-15 2023-10-24 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 누트린-3a 및 펩티드에 의한 폐 섬유증의 저해
CN104274827B (zh) 2013-07-01 2020-07-14 上海贺普药业股份有限公司 贺普拉肽的制剂
EP3065705A4 (en) 2013-11-04 2017-10-18 Board of Regents, The University of Texas System Compositions and methods for administration of an enzyme to a subject's airway
EP3074034B1 (en) * 2013-11-26 2019-05-01 E & B Technologies LLC Treatment of inflammatory disease using caveolin linked to an internalisation peptide
US9908915B2 (en) * 2013-11-26 2018-03-06 Yale University Cell-penetrating compositions and methods using same
JP6866296B2 (ja) * 2015-02-27 2021-04-28 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System ポリペプチド治療及びその使用
KR101845590B1 (ko) * 2015-09-25 2018-04-05 단국대학교 천안캠퍼스 산학협력단 유전자를 이용한 폐암 예후예측용 조성물
CN107216394B (zh) * 2017-06-21 2020-10-09 江南大学 一种小窝蛋白-1脚手架区融合多肽的制备方法及其应用
US20190224243A1 (en) 2018-01-25 2019-07-25 Musc Foundation For Research Development Enhancement of the Beneficial Effects of Mesenchymal Stem Cell Treatment by the Caveolin-1 Scaffolding Domain Peptide and Subdomains
KR102958241B1 (ko) 2018-09-10 2026-04-30 레인 테라퓨틱스, 인크. Cav-1 단백질의 변형된 펩타이드 단편 및 섬유증의 치료에 있어서 이의 용도
WO2020055824A1 (en) 2018-09-10 2020-03-19 Board of Regents, The University of the Texas System Dry powder formulation of caveolin-1 peptides and methods of use thereof
US20240082342A1 (en) 2018-11-21 2024-03-14 Board Of Regents, The University Of Texas System Peptide therapeutics for increasing lung cell viability
WO2020106922A1 (en) 2018-11-21 2020-05-28 Board Of Regents, The University Of Texas System Peptide therapeutics for acute and chronic airway and alveolar diseases
WO2020185826A1 (en) * 2019-03-11 2020-09-17 Lung Therapeutics, Inc. Compositions and methods for protecting type 2 alveolar epithelial cells (aec2)
US12097222B2 (en) 2019-06-06 2024-09-24 Spiritus Therapeutics, Inc. Methods for attenuating viral infection and for treating lung injury
CN111671886B (zh) 2020-03-05 2022-11-15 上海甘翼生物医药科技有限公司 一种预防高危易感人群感染冠状病毒或发生冠状病毒感染疾病的药物组合及其用途
WO2021216659A1 (en) 2020-04-21 2021-10-28 Lung Therapeutics, Inc. Modified peptide fragments of cav-1 protein and uses thereof
EP4168031A4 (en) 2020-06-19 2024-07-10 Lung Therapeutics, LLC MODIFIED CAVEOLIN-1 PEPTIDES FOR THE TREATMENT OF PATHOGEN-INDUCED LUNG LESION
EP4297768A4 (en) 2021-02-25 2025-01-15 Lung Therapeutics, LLC Biomarkers for the treatment of interstitial lung disease
US12449810B2 (en) 2021-03-01 2025-10-21 The Boeing Company Autonomous maneuver generation to mate connectors
US20250041383A1 (en) 2021-06-17 2025-02-06 Lung Therapeutics, Inc. Modified caveolin-1 peptides for the treatment of post-acute covid-19
JP2024539242A (ja) 2021-10-22 2024-10-28 ラング セラピューティクス,エルエルシー 慢性腎疾患の治療のための改変カベオリン-1ペプチド

Similar Documents

Publication Publication Date Title
ES2203470T3 (es) Nuevas composiciones de medicamentos a base de bromuro de tiotropio y salmeterol.
AU2025204271A1 (en) Microcrystalline diketopiperazine compositions and methods
US6616914B2 (en) Method for pulmonary and oral delivery of pharmaceuticals
Yan et al. Nebulized inhalation drug delivery: clinical applications and advancements in research
AU2025267377A1 (en) Pulsed Administration Of Inhaled Nitric Oxide For The Treatment Of Pulmonary Hypertension
JP2019528320A5 (enExample)
RU2018138195A (ru) Соединения 3,5-диамино-6-хлор-n-(n-(4- фенилбутил)карбамимидоил)пиразин-2-карбоксамида
US20090227511A1 (en) Methods and compositions for treating lesions of the respiratory epithelium
JP2014518268A5 (enExample)
JP2023522010A5 (enExample)
JP2022530637A5 (enExample)
Shah et al. Pulmonary drug delivery: a promising approach
JP2022500078A5 (enExample)
CN102186458A (zh) 治疗慢性阻塞性肺病及其它肺疾病的方法
JP2009529539A (ja) 呼吸器障害を治療するための方法および組成物
JP2002532520A (ja) 気道病治療および気道用薬剤送達のための化合物および方法
JP2023523557A5 (enExample)
WO2006008517A2 (en) Use of dry powder compositions for pulmonary delivery
JPH03215420A (ja) 呼吸疾患又は障害の治療に関するバニロイド類の用途
JP2001505553A (ja) ウリジン三リン酸および関連化合物で気管支炎を治療する方法
US20250228779A1 (en) Method and composition for treating pulmonary fibrosis
JP2003525232A (ja) 肺送達のための治療用組成物
JP2023524064A5 (enExample)
JP2008516991A5 (enExample)
CA2516322A1 (en) Glycosaminoglycan-dnase combination therapy